SMARCB1 is an inclusion criterion in 18 clinical trials for malignant solid tumor, of which 15 are open and 3 are closed. Of the trials that contain SMARCB1 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [4].

SMARCB1 is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain SMARCB1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

SMARCB1 is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain SMARCB1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

SMARCB1 is an inclusion criterion in 6 clinical trials for rhabdoid tumor, of which 5 are open and 1 is closed. Of the trials that contain SMARCB1 status and rhabdoid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (4 open) [4].

SMARCB1 is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain SMARCB1 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain SMARCB1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

SMARCB1 is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain SMARCB1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 3 clinical trials for epithelioid sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

SMARCB1 is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain SMARCB1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 3 clinical trials for synovial sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 status and synovial sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for atypical teratoid/rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for hepatoblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for kidney medullary carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and kidney medullary carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for rhabdoid tumor of the kidney, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 0 are open and 2 are closed. Of the trials that contain SMARCB1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and chordoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for dedifferentiated chordoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and dedifferentiated chordoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for extrarenal rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and extrarenal rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for small cell undifferentiated hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and small cell undifferentiated hepatoblastoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for unclassified renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and unclassified renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

SMARCB1 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].